0000000000406923

AUTHOR

Rosa De Simone

showing 7 related works from this author

Cross-over study on effects of Mediterranean diet in two randomly selected population samples

2003

Abstract Two randomly selected population samples in Western Sicily, one rural (n = 40) and one urban (n = 40), were studied to evaluate the impact of dietary intervention on lipid, coagulative and fibrinolytic parameters. The two groups received the diets in a cross-over design with the following sequences: (a) baseline period; (b) 8-week dietary intervention period; (c) 8-week return to the original diet. During (a) and (c) all subjects consumed their usual diet. During the dietary intervention period (b), the rural sample consumed the urban sample's diet, while the urban sample consumed the rural sample's diet (the so-called “Mediterranean diet”). At baseline, after 8 weeks' dietary inte…

chemistry.chemical_classificationeducation.field_of_studymedicine.medical_specialtyNutrition and DieteticsMediterranean dietbusiness.industryEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPopulationCrossover studyEndocrinologyAnimal scienceEndocrinologychemistryInternal medicineFibrinolysisSaturated fatty acidmedicineeducationbusinessPlasminogen activatorCompletely randomized designPolyunsaturated fatty acidNutrition Research
researchProduct

Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients.

1997

This study was conducted to identify the mechanisms responsible for coagulative and fibrinolytic alterations and to study the effects of a short-term treatment with low-dose heparin on hemostatic abnormalities in obese non-insulin-dependent diabetes mellitus (NIDDM) patients. Four groups of age- and sex-matched patients were studied: (1) lean nondiabetic subjects (n = 30) with a body mass index (BMI) less than 25 kg/m2 (lean control subjects), (2) obese nondiabetic subjects (n = 30) with a BMI greater than 30 kg/m2 (obese control subjects), (3) lean NIDDM patients (n = 30), and (4) obese NIDDM patients (n = 30). All subjects were tested on the following parameters: fibrinogen, factor VII, p…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenTissue plasminogen activatorBody Mass Indexchemistry.chemical_compoundEndocrinologyInternal medicineFibrinolysismedicineHumansInsulinObesityBlood CoagulationHemostasisFactor VIIbusiness.industryHeparinFibrinolysisnutritional and metabolic diseasesAnticoagulantsHeparinMiddle AgedLipidsBlood Coagulation FactorsEndocrinologychemistryDiabetes Mellitus Type 2HemostasisCase-Control StudiesFemalebusinessPlasminogen activatorBody mass indexmedicine.drugMetabolism: clinical and experimental
researchProduct

Effetto di due vini rossi siciliani su alcuni fattori di rischio cardiovascolare

2004

Background. The aim of this study was to evaluate whether Sicilian red wine consumption is associated with a lower cardiovascular risk. Methods. Forty-eight subjects of both sexes (age range 35-65 years) nondrinkers or rarely drinkers of moderate red wine intake were selected. Subjects were divided into two groups (group A and group B), assigned to receive with a crossover design 250 ml/die (during the meals) of one of two types of Sicilian red wines (Nero d’Avola and Etna Torrepalino respectively). At all visits (-15 days, basal, +4 and +8 weeks) the following parameters were measured: blood glucose, total cholesterol and triglycerides (by enzyme kit methods, Boehringer Mannheim, Milan, It…

Settore MED/09 - Medicina InternaRisk factors.AntioxidantDiet
researchProduct

Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIb hyperlipoproteinemia

1994

Abstract A randomized, double-blind, parallel-group study of pravastatin versus placebo was carried out for 24 weeks in 20 patients with type IIb primary hyperlipoproteinemia. Total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, blood glucose, apolipoproteins (apo) A1 and B, and lipoprotein (a) (Lp[a]) levels were determined. A venous occlusion test was also performed in all patients. Pre- and postvenous occlusion tests were determined: tissue plasminogen activator antigen (t-PA[Ag]), plasminogen activator inhibitor (PAI) activity, factor VII, fibrinogen, plasminogen, and hematocrit. Compared with placebo, pravastatin signi…

Pharmacologymedicine.medical_specialtyApolipoprotein BbiologyTriglyceridebusiness.industryCholesterolmedicine.medical_treatmentnutritional and metabolic diseasesFibrinogenchemistry.chemical_compoundEndocrinologychemistryInternal medicineFibrinolysismedicinebiology.proteinlipids (amino acids peptides and proteins)Pharmacology (medical)businessPlasminogen activatorPravastatinmedicine.drugLipoproteinCurrent Therapeutic Research
researchProduct

Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution

1994

Recently waist/hip ratio (WHR), a marker of body fat distribution, has been described as a risk factor for cardiovascular disease (CVD). The aim of the present study was to evaluate the influence of body fat distribution on metabolic, haemostatic and haemorheological pattern in premenopausal obese women with different WHR. Fourty premenopausal obese women were subdivided into two groups, matched for age and body mass index (BMI): 20 women with abdominal obesity (WHR = 0.94 +/- 0.02) and 20 women with peripheral obesity (WHR = 0.77 +/- 0.03). Twenty nonobese women were recruited as control group. The abdominal obesity group had significantly higher blood glucose, triglycerides, total cholest…

Adultmedicine.medical_specialtymedicine.medical_treatmentFibrinogenchemistry.chemical_compoundHigh-density lipoproteinRisk FactorsInternal medicineFibrinolysismedicineHumansObesityBlood CoagulationAbdominal obesitybiologybusiness.industryCholesterolFibrinolysisFibrinogenBlood ProteinsHematologyFactor VIIBlood Viscositymedicine.diseaseLipidsObesityEndocrinologyHematocritPremenopausechemistryCardiovascular DiseasesHemorheologybiology.proteinBody ConstitutionFemaleApolipoprotein A1medicine.symptombusinessBody mass indexmedicine.drugThrombosis Research
researchProduct

Toward the Discovery of New Agents Able to Inhibit the Expression of Microsomal Prostaglandin E Synthase-1 Enzyme as Promising Tools in Drug Developm…

2010

In our recent studies, we focused our attention on the synthesis of several γ-hydroxybutenolides designed on the basis of petrosaspongiolide M 1 (PM) structure that has been recognized to potently inhibit the inflammatory process through the selective PLA2 enzyme inhibition. By means of a combination of computational methods and efficient synthetic strategies, we generated small collections of PM modified analogs to identify new potent PLA2 inhibitors, suitable for clinical development. In the course of the biological screening of our compounds, we discovered a potent and selective inhibitor of mPGES-1 expression, the benzothiophene γ-hydroxybutenolide 2, which so far represents the only pr…

Pharmacologychemistry.chemical_classificationOrganic ChemistryBenzothiopheneInflammationPharmacologyResveratrolmedicine.disease_causeBiochemistrychemistry.chemical_compoundEnzymeBiochemistryDownregulation and upregulationchemistryDrug developmentCell cultureDrug DiscoverymedicineMolecular Medicinelipids (amino acids peptides and proteins)medicine.symptomCarcinogenesisChemical Biology & Drug Design
researchProduct

Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia

1992

Abstract The effect of gemfibrozil on lipidic, coagulative, and fibrinolytic pattern was studied in 20 patients with primary type IV hyperlipoproteinemia. After a 4-week stabilization period during which administration of lipid-lowering drugs was stopped and an isocaloric diet (20% protein, 30% fat, and 50% carbohydrates) was prescribed, 20 patients (12 men and 8 women; mean age, 38 ± 4 years; body mass index, 23.4 ± 1.5) suffering from primary hypertriglyceridemia were included in this study and treated for a 12-week period with gemfibrozil (600 mg BID). Every 4 weeks the following parameters were checked: glycemia, triglycerides, total cholesterol, high density lipoprotein-cholesterol, to…

Pharmacologymedicine.medical_specialtyFactor VIIbusiness.industrymedicine.medical_treatmentHypertriglyceridemiaAntithrombinmedicine.diseaseFibrinogenchemistry.chemical_compoundEndocrinologychemistryHemostasisInternal medicineFibrinolysismedicineGemfibrozillipids (amino acids peptides and proteins)Pharmacology (medical)businessPlasminogen activatormedicine.drugCurrent Therapeutic Research
researchProduct